{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:10:13Z","timestamp":1779239413810,"version":"3.51.4"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203072"],"award-info":[{"award-number":["82203072"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71144-1","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:46:51Z","timestamp":1774604811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4\/6 inhibitor resistance in estrogen receptor-positive cancers"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaochuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shini","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dezheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanmiao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-5809","authenticated-orcid":false,"given":"Shuqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1639","authenticated-orcid":false,"given":"Peng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6900-2217","authenticated-orcid":false,"given":"Zhaoliang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"71144_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353\u2013367 (2016).","journal-title":"Cancer Discov."},{"key":"71144_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"71144_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The effect of abemaciclib plus Fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"71144_CR4","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1136\/ijgc-2023-004739","volume":"33","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. The promise of combining CDK4\/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma. Int. J. Gynecol. Cancer 33, 1943\u20131949 (2023).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"71144_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.22.00628","volume":"41","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos, P. A. et al. A Phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer. J. Clin. Oncol. 41, 599\u2013608 (2023).","journal-title":"J. Clin. Oncol."},{"key":"71144_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000926","volume":"5","author":"G Colon-Otero","year":"2020","unstructured":"Colon-Otero, G. et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open 5, e000926 (2020).","journal-title":"ESMO Open"},{"key":"71144_CR7","doi-asserted-by":"publisher","unstructured":"Mirza, M. R. et al. LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced\/recurrent endometrial cancer (EC): NSGO-PALEO\/ENGOT-EN3 trial. Ann. Oncol. 31 https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2258 (2020).","DOI":"10.1016\/j.annonc.2020.08.2258"},{"key":"71144_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M Alvarez-Fernandez","year":"2020","unstructured":"Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"71144_CR9","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus Fulvestrant in the PALOMA-3 trial. Cancer Discov. 8, 1390\u20131403 (2018).","journal-title":"Cancer Discov."},{"key":"71144_CR10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174\u20131193 (2020).","journal-title":"Cancer Discov."},{"key":"71144_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa, C. et al. PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3Kalpha inhibitors in breast cancer. Cancer Discov. 10, 72\u201385 (2020).","journal-title":"Cancer Discov."},{"key":"71144_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell 34, 893\u2013905.e8 (2018).","journal-title":"Cancer Cell"},{"key":"71144_CR13","doi-asserted-by":"publisher","unstructured":"Kudo, R. et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2024.09.009 (2024).","DOI":"10.1016\/j.ccell.2024.09.009"},{"key":"71144_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01642-5","volume":"21","author":"H Mo","year":"2022","unstructured":"Mo, H. et al. S6K1 amplification confers innate resistance to CDK4\/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. Mol. Cancer 21, 171 (2022).","journal-title":"Mol. Cancer"},{"key":"71144_CR15","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene 36, 2255\u20132264 (2017).","journal-title":"Oncogene"},{"key":"71144_CR16","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41388-018-0650-0","volume":"38","author":"ES Knudsen","year":"2019","unstructured":"Knudsen, E. S. et al. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4\/6 inhibition in patient-derived models of pancreatic cancer. Oncogene 38, 3355\u20133370 (2019).","journal-title":"Oncogene"},{"key":"71144_CR17","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/0008-5472.CAN-17-3124","volume":"78","author":"I Olmez","year":"2018","unstructured":"Olmez, I. et al. Combined c-Met\/Trk inhibition overcomes resistance to CDK4\/6 inhibitors in glioblastoma. Cancer Res. 78, 4360\u20134369 (2018).","journal-title":"Cancer Res."},{"key":"71144_CR18","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner, N. M. et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin. Cancer Res. 25, 3996\u20134013 (2019).","journal-title":"Clin. Cancer Res."},{"key":"71144_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano, L. et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat. Commun. 10, 1373 (2019).","journal-title":"Nat. Commun."},{"key":"71144_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt, A. C. et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat. Cancer 2, 34\u201348 (2021).","journal-title":"Nat. Cancer"},{"key":"71144_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s43018-024-00740-1","volume":"5","author":"S Park","year":"2024","unstructured":"Park, S. et al. A deep learning model of tumor cell architecture elucidates response and resistance to CDK4\/6 inhibitors. Nat. Cancer 5, 996\u20131009 (2024).","journal-title":"Nat. Cancer"},{"key":"71144_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","volume":"14","author":"M Esteller","year":"2024","unstructured":"Esteller, M. et al. The epigenetic hallmarks of cancer. Cancer Discov. 14, 1783\u20131809 (2024).","journal-title":"Cancer Discov."},{"key":"71144_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang, N., Ma, T. & Yu, B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct. Target. Ther. 8, 69 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"71144_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304619121","volume":"121","author":"Z Yu","year":"2024","unstructured":"Yu, Z. et al. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proc. Natl. Acad. Sci. USA 121, e2304619121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71144_CR25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.CD-17-0375","volume":"7","author":"X Yao","year":"2017","unstructured":"Yao, X. et al. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 7, 1284\u20131305 (2017).","journal-title":"Cancer Discov."},{"key":"71144_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh3462","volume":"13","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Super-enhancer landscape reveals leukemia stem cell reliance on X-box binding protein 1 as a therapeutic vulnerability. Sci. Transl. Med. 13, eabh3462 (2021).","journal-title":"Sci. Transl. Med."},{"key":"71144_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101162","volume":"4","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep. Med. 4, 101162 (2023).","journal-title":"Cell Rep. Med."},{"key":"71144_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401399","volume":"11","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Lactylation-driven IGF2BP3-mediated serine metabolism reprogramming and RNA m6A-modification promotes lenvatinib resistance in HCC. Adv. Sci. 11, e2401399 (2024).","journal-title":"Adv. Sci."},{"key":"71144_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","volume":"13","author":"L Sun","year":"2022","unstructured":"Sun, L., Zhang, H. & Gao, P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell 13, 877\u2013919 (2022).","journal-title":"Protein Cell"},{"key":"71144_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s42255-023-00883-y","volume":"5","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat. Metab. 5, 1765\u20131786 (2023).","journal-title":"Nat. Metab."},{"key":"71144_CR31","doi-asserted-by":"crossref","unstructured":"Canete, A., Cano, E., Munoz-Chapuli, R. & Carmona, R. Role of vitamin A\/retinoic acid in regulation of embryonic and adult hematopoiesis. Nutrients 9, 159 (2017).","DOI":"10.3390\/nu9020159"},{"key":"71144_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/1535-7163.MCT-24-0367","volume":"24","author":"PC Jones","year":"2025","unstructured":"Jones, P. C. & Von Hoff, D. D. Vitamin A metabolism and resistance of hepatic metastases to immunotherapy. Mol. Cancer Ther. 24, 345\u2013353 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"71144_CR33","doi-asserted-by":"crossref","unstructured":"Brown, G. Targeting the retinoic acid pathway to eradicate cancer stem cells. Int. J. Mol. Sci. 24, 2373 (2023).","DOI":"10.3390\/ijms24032373"},{"key":"71144_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1042\/bj3050681","volume":"305","author":"FDJ Labrecque","year":"1995","unstructured":"Labrecque, F. D. J., Lacroix, A. & Bhat, P. V. A novel isoenzyme of aldehyde dehydrogenase specifically involved in the biosynthesis of 9-cis and all-trans retinoic acid.  Biochem. J. 305, 681\u2013684 (1995).","journal-title":"Biochem. J."},{"key":"71144_CR35","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","volume":"76","author":"Y Yokoyama","year":"2016","unstructured":"Yokoyama, Y. et al. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Res. 76, 6320\u20136330 (2016).","journal-title":"Cancer Res."},{"key":"71144_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7150\/thno.88057","volume":"14","author":"I Gorodetska","year":"2024","unstructured":"Gorodetska, I. et al. ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription. Theranostics 14, 714\u2013737 (2024).","journal-title":"Theranostics"},{"key":"71144_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10409238.2020.1828260","volume":"55","author":"C de Ceuninck van Capelle","year":"2020","unstructured":"de Ceuninck van Capelle, C., Spit, M. & Ten Dijke, P. Current perspectives on inhibitory SMAD7 in health and disease. Crit. Rev. Biochem. Mol. Biol. 55, 691\u2013715 (2020).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"71144_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","volume":"26","author":"JI Fletcher","year":"2016","unstructured":"Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D. & Haber, M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist. Updates 26, 1\u20139 (2016).","journal-title":"Drug Resist. Updates"},{"key":"71144_CR39","doi-asserted-by":"crossref","unstructured":"Casamassimi, A. et al. Multifaceted role of PRDM proteins in human cancer. Int. J. Mol. Sci. 21, 2648 (2020).","DOI":"10.3390\/ijms21072648"},{"key":"71144_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcmm.12403","volume":"19","author":"CE Chua","year":"2015","unstructured":"Chua, C. E. & Tang, B. L. The role of the small GTPase Rab31 in cancer. J. Cell Mol. Med. 19, 1\u201310 (2015).","journal-title":"J. Cell Mol. Med."},{"key":"71144_CR41","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical Stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"71144_CR42","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"71144_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00411-x","volume":"7","author":"K Lavudi","year":"2023","unstructured":"Lavudi, K. et al. ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase theta expression. npj Precis. Oncol. 7, 66 (2023).","journal-title":"npj Precis. Oncol."},{"key":"71144_CR44","doi-asserted-by":"publisher","first-page":"7122","DOI":"10.7150\/thno.35729","volume":"9","author":"HM Lei","year":"2019","unstructured":"Lei, H. M. et al. Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. Theranostics 9, 7122\u20137139 (2019).","journal-title":"Theranostics"},{"key":"71144_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/0008-5472.CAN-23-1749","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu, X. Co-targeting CDK4 6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer. Cancer Res. 84, 1333\u20131351 (2024).","journal-title":"Cancer Res."},{"key":"71144_CR46","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.18632\/oncotarget.6920","volume":"7","author":"H Tomita","year":"2016","unstructured":"Tomita, H., Tanaka, T. & Hara, A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7, 11018\u201311032 (2016).","journal-title":"Oncotarget"},{"key":"71144_CR47","doi-asserted-by":"publisher","first-page":"775","DOI":"10.5851\/kosfa.2022.e46","volume":"42","author":"DY Lee","year":"2022","unstructured":"Lee, D. Y. et al. Review of the current research on fetal bovine serum and the development of cultured meat. Food Sci. Anim. Resour. 42, 775\u2013799 (2022).","journal-title":"Food Sci. Anim. Resour."},{"key":"71144_CR48","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","volume":"81","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 81, 5919\u20135934 (2021).","journal-title":"Cancer Res."},{"key":"71144_CR49","doi-asserted-by":"crossref","unstructured":"Bian, Y. et al. Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. Redox Biol. 77, 103361 (2024).","DOI":"10.1016\/j.redox.2024.103361"},{"key":"71144_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11427-021-2140-8","volume":"66","author":"Z Cai","year":"2023","unstructured":"Cai, Z. et al. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4\/6 inhibitor in breast cancer that can be reversed by PI3K\/mTOR inhibitors. Sci. China Life Sci. 66, 94\u2013109 (2023).","journal-title":"Sci. China Life Sci."},{"key":"71144_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","volume":"42","author":"XQ Xu","year":"2021","unstructured":"Xu, X. Q. et al. Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies. Acta Pharm. Sin. 42, 171\u2013178 (2021).","journal-title":"Acta Pharm. Sin."},{"key":"71144_CR52","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"71144_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrg.2017.102","volume":"19","author":"VK Dhiman","year":"2018","unstructured":"Dhiman, V. K., Bolt, M. J. & White, K. P. Nuclear receptors in cancer\u2014uncovering new and evolving roles through genomic analysis. Nat. Rev. Genet. 19, 160\u2013174 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"71144_CR54","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molcel.2010.10.028","volume":"40","author":"SA Miller","year":"2010","unstructured":"Miller, S. A., Mohn, S. E. & Weinmann, A. S. Jmjd3 and UTX play a demethylase-independent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol. Cell 40, 594\u2013605 (2010).","journal-title":"Mol. Cell"},{"key":"71144_CR55","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2009.04.043","volume":"137","author":"S Hua","year":"2009","unstructured":"Hua, S., Kittler, R. & White, K. P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259\u20131271 (2009).","journal-title":"Cell"},{"key":"71144_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2014.08.027","volume":"159","author":"Z Liu","year":"2014","unstructured":"Liu, Z. et al. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159, 358\u2013373 (2014).","journal-title":"Cell"},{"key":"71144_CR57","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","volume":"19","author":"ME Urick","year":"2019","unstructured":"Urick, M. E. & Bell, D. W. Clinical actionability of molecular targets in endometrial cancer. Nat. Rev. Cancer 19, 510\u2013521 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"71144_CR58","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","volume":"9","author":"H Qian","year":"2023","unstructured":"Qian, H. et al. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets. Cell Death Discov. 9, 470 (2023).","journal-title":"Cell Death Discov."},{"key":"71144_CR59","doi-asserted-by":"crossref","unstructured":"Sabari, B. R. et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science 361, eaar3958 (2018).","DOI":"10.1126\/science.aar3958"},{"key":"71144_CR60","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee, N. & Gupta, R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 81, 5589\u20135595 (2021).","journal-title":"Cancer Res."},{"key":"71144_CR61","doi-asserted-by":"crossref","unstructured":"Liu, S. et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. J. Clin. Investig. 131, e145035 (2021).","DOI":"10.1172\/JCI145035"},{"key":"71144_CR62","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-21-0910","volume":"12","author":"AK Biswas","year":"2022","unstructured":"Biswas, A. K. et al. Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov. 12, 1002\u20131021 (2022).","journal-title":"Cancer Discov."},{"key":"71144_CR63","doi-asserted-by":"crossref","unstructured":"Loh, W. et al. Association between vitamin A and E forms and prostate cancer risk in the Singapore Prostate Cancer Study. Nutrients 15, 2677 (2023).","DOI":"10.3390\/nu15122677"},{"key":"71144_CR64","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/aje\/kwq429","volume":"173","author":"AM Mondul","year":"2011","unstructured":"Mondul, A. M. et al. Serum retinol and risk of prostate cancer. Am. J. Epidemiol. 173, 813\u2013821 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"71144_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1017\/S000711451900120X","volume":"122","author":"L Xie","year":"2019","unstructured":"Xie, L. et al. Association of plasma retinol levels with incident cancer risk in Chinese hypertensive adults: a nested case-control study. Br. J. Nutr. 122, 293\u2013300 (2019).","journal-title":"Br. J. Nutr."},{"key":"71144_CR66","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","volume":"334","author":"GS Omenn","year":"1996","unstructured":"Omenn, G. S. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.  N. Engl. J. Med. 334, 1150\u20131155 (1996).","journal-title":"N. Engl. J. Med."},{"key":"71144_CR67","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/jnci\/88.21.1560","volume":"88","author":"D Albanes","year":"1996","unstructured":"Albanes, D. et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 88, 1560\u20131570 (1996).","journal-title":"J. Natl. Cancer Inst."},{"key":"71144_CR68","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s43018-023-00622-y","volume":"4","author":"J Taylor","year":"2023","unstructured":"Taylor, J. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat. Cancer 4, 1544\u20131560 (2023).","journal-title":"Nat. Cancer"},{"key":"71144_CR69","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.devcel.2023.08.028","volume":"58","author":"KM Ferguson","year":"2023","unstructured":"Ferguson, K. M. et al. Palbociclib releases the latent differentiation capacity of neuroblastoma cells. Dev. Cell 58, 1967\u20131982.e8 (2023).","journal-title":"Dev. Cell"},{"key":"71144_CR70","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/1535-7163.MCT-23-0528","volume":"23","author":"L Hu","year":"2024","unstructured":"Hu, L. et al. The CDK4\/6 inhibitor palbociclib synergizes with ATRA to induce differentiation in AML. Mol. Cancer Ther. 23, 961\u2013972 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"71144_CR71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1046\/j.1432-0436.1995.5910061.x","volume":"59","author":"G Han","year":"1995","unstructured":"Han, G., Chang, B., Connor, M. J. & Sidell, N. Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells. Differentiation 59, 61\u201369 (1995).","journal-title":"Differentiation"},{"key":"71144_CR72","doi-asserted-by":"crossref","unstructured":"Bayeva, N., Coll, E. & Piskareva, O. Differentiating neuroblastoma: a systematic review of the retinoic acid, its derivatives, and synergistic interactions. J. Pers. Med. 11, 211 (2021).","DOI":"10.3390\/jpm11030211"},{"key":"71144_CR73","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G. & Pelosi, E. Recent developments in differentiation therapy of acute myeloid leukemia. Cancers 17, 1141 (2025).","DOI":"10.3390\/cancers17071141"},{"key":"71144_CR74","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1093\/nar\/gkac778","volume":"50","author":"ZZ Zheng","year":"2022","unstructured":"Zheng, Z. Z. et al. Super-enhancer-controlled positive feedback loop BRD4\/ERalpha-RET-ERalpha promotes ERalpha-positive breast cancer. Nucleic Acids Res. 50, 10230\u201310248 (2022).","journal-title":"Nucleic Acids Res."},{"key":"71144_CR75","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cell.2013.10.056","volume":"155","author":"W Liu","year":"2013","unstructured":"Liu, W. et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 155, 1581\u20131595 (2013).","journal-title":"Cell"},{"key":"71144_CR76","doi-asserted-by":"crossref","unstructured":"Ghyselinck, N. B. & Duester, G. Retinoic acid signaling pathways. Development 146, dev167502 (2019).","DOI":"10.1242\/dev.167502"},{"key":"71144_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","volume":"41","author":"A di Masi","year":"2015","unstructured":"di Masi, A. et al. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol. Asp. Med. 41, 1\u2013115 (2015).","journal-title":"Mol. Asp. Med."},{"key":"71144_CR78","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1182\/blood.2020005698","volume":"137","author":"Tan,Y","year":"2021","unstructured":"Tan,Y et al. A PML RAR\u03b1 direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia. Blood 137, 1503\u20131516 (2021).","journal-title":"Blood"},{"key":"71144_CR79","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11684-017-0604-x","volume":"12","author":"Q Luo","year":"2018","unstructured":"Luo, Q., Deng, W., Wang, H., Fan, H. & Zhang, J. BRD4 interacts with PML\/RARalpha in acute promyelocytic leukemia. Front. Med. 12, 726\u2013734 (2018).","journal-title":"Front. Med."},{"key":"71144_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1039\/D2MO00285J","volume":"19","author":"B Kumar","year":"2023","unstructured":"Kumar, B. et al. Role of identified proteins in the proteome profiles of CDK4\/6 inhibitor-resistant breast cancer cell lines. Mol. Omics 19, 404\u2013417 (2023).","journal-title":"Mol. Omics"},{"key":"71144_CR81","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s12282-020-01090-3","volume":"27","author":"M Iida","year":"2020","unstructured":"Iida, M. et al. Decreased ER dependency after acquired resistance to CDK4\/6 inhibitors. Breast Cancer 27, 963\u2013972 (2020).","journal-title":"Breast Cancer"},{"key":"71144_CR82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","volume":"14","author":"B Kingston","year":"2024","unstructured":"Kingston, B. et al. ESR1 F404 mutations and acquired resistance to Fulvestrant in ESR1-mutant breast cancer. Cancer Discov. 14, 274\u2013289 (2024).","journal-title":"Cancer Discov."},{"key":"71144_CR83","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/0008-5472.CAN-16-1593","volume":"77","author":"T Shibata","year":"2017","unstructured":"Shibata, T. et al. Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression. Cancer Res. 77, 545\u2013556 (2017).","journal-title":"Cancer Res."},{"key":"71144_CR84","doi-asserted-by":"crossref","unstructured":"Crucitta, S. et al. CDK4\/6 inhibitors overcome endocrine ESR1 mutation-related resistance in metastatic breast cancer patients. Cancers 15, 1306 (2023).","DOI":"10.3390\/cancers15041306"},{"key":"71144_CR85","doi-asserted-by":"publisher","first-page":"EVIDoa2300231","DOI":"10.1056\/EVIDoa2300231","volume":"3","author":"MR Lloyd","year":"2024","unstructured":"Lloyd, M. R. et al. CDK4\/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid. 3, EVIDoa2300231 (2024).","journal-title":"NEJM Evid."},{"key":"71144_CR86","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1074\/jbc.RA120.013666","volume":"295","author":"SC Hewitt","year":"2020","unstructured":"Hewitt, S. C., Grimm, S. A., Wu, S. P., DeMayo, F. J. & Korach, K. S. Estrogen receptor alpha (ERalpha)-binding super-enhancers drive key mediators that control uterine estrogen responses in mice. J. Biol. Chem. 295, 8387\u20138400 (2020).","journal-title":"J. Biol. Chem."},{"key":"71144_CR87","doi-asserted-by":"publisher","first-page":"e60516","DOI":"10.1371\/journal.pone.0060516","volume":"8","author":"HX Lin","year":"2013","unstructured":"Lin, H. X. et al. Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS ONE 8, e60516 (2013).","journal-title":"PLoS ONE"},{"key":"71144_CR88","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/rcm.5073","volume":"25","author":"O Midttun","year":"2011","unstructured":"Midttun, O. & Ueland, P. M. Determination of vitamins A, D and E in a small volume of human plasma by a high-throughput method based on liquid chromatography\/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25, 1942\u20131948 (2011).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"71144_CR89","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/jms.1777","volume":"45","author":"H Horai","year":"2010","unstructured":"Horai, H. et al. MassBank: a public repository for sharing mass spectral data for life sciences. J. Mass Spectrom. 45, 703\u2013714 (2010).","journal-title":"J. Mass Spectrom."},{"key":"71144_CR90","doi-asserted-by":"publisher","first-page":"D527","DOI":"10.1093\/nar\/gkl838","volume":"35","author":"M Sud","year":"2007","unstructured":"Sud, M. et al. LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35, D527\u2013D532 (2007).","journal-title":"Nucleic Acids Res."},{"key":"71144_CR91","doi-asserted-by":"publisher","first-page":"32548","DOI":"10.1039\/D0RA05326K","volume":"10","author":"S Abdelrazig","year":"2020","unstructured":"Abdelrazig, S. et al. Metabolic characterisation of Magnetospirillum gryphiswaldense MSR-1 using LC-MS-based metabolite profiling. RSC Adv. 10, 32548\u201332560 (2020).","journal-title":"RSC Adv."},{"key":"71144_CR92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata, H. et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27, 29\u201334 (1999).","journal-title":"Nucleic Acids Res."},{"key":"71144_CR93","doi-asserted-by":"publisher","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","volume":"50","author":"DS Wishart","year":"2022","unstructured":"Wishart, D. S. et al. HMDB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res. 50, D622\u2013D631 (2022).","journal-title":"Nucleic Acids Res."},{"key":"71144_CR94","doi-asserted-by":"publisher","first-page":"F857","DOI":"10.1152\/ajprenal.00513.2015","volume":"310","author":"DA Kieffer","year":"2016","unstructured":"Kieffer, D. A. et al. Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am. J. Physiol. Ren. Physiol. 310, F857\u2013F871 (2016).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"71144_CR95","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"71144_CR96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"71144_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"71144_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"71144_CR99","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"71144_CR100","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"71144_CR101","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/nprot.2012.101","volume":"7","author":"J Feng","year":"2012","unstructured":"Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 7, 1728\u20131740 (2012).","journal-title":"Nat. Protoc."},{"key":"71144_CR102","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"71144_CR103","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gku365","volume":"42","author":"F Ramirez","year":"2014","unstructured":"Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187\u2013W191 (2014).","journal-title":"Nucleic Acids Res."},{"key":"71144_CR104","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsdottir","year":"2013","unstructured":"Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178\u2013192 (2013).","journal-title":"Brief. Bioinform."},{"key":"71144_CR105","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2509255122","volume":"122","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer. Proc. Natl. Acad. Sci. USA 122, e2509255122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71144-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:02:31Z","timestamp":1779238951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71144-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71144"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71144-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4507"}}